Genscript Biotech Unit Logs $286 Million in Sales from Carvykti in July-September

MT Newswires Live10-16

Genscript Biotech (HKG:1548) subsidiary Legend Biotech logged $286 million in net trade sales from its Carvykti medication in the quarter ended Sept. 30, according to a Tuesday filing with the Hong Kong Stock Exchange.

Carvykti is indicated for the treatment of multiple myeloma or cancer of the bone marrow, according to a note on its website.

Price (HKD): $11.92, Change: $-0.020, Percent Change: -0.17%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment